BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
PROPEL 3, the Phase 3 clinical trial of infigratinib in achondroplasia, successfully achieved its pre-specified primary efficacy endpoint of change from baseline in absolute height velocity (AHV) at ...
BridgeBio Pharma (NASDAQ:BBIO) executives used the company’s fourth-quarter 2025 earnings call to highlight accelerating commercial performance for its transthyretin amyloid cardiomyopathy (ATTR-CM) d ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results